Korean pharmaceutical firms challenge Pfizer's Norvasc

Published: 2004-06-30 07:00:00

Updated: 2004-06-30 07:00:00

Korean major pharmaceutical markers are set to challenge Pfizer's current lead in the domestic amlodipine market by strategically launching their novel amlopdipine salts for sales boost, according to industry sources recently.

Following their products' approval from the Korea Food and Drug Administration, four Korean companies, such as Hanmi (amolipine camsylate), SK Pharm (amodipine maleate...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.